Fresenius: Barclays upgrades stock
(CercleFinance.com) - Barclays has upgraded its rating on the Fresenius from "equal weight to "overweight," having raised its target price from 53 euros to 55 euros, in comments on the European medical services and technologies sector.
"As the world approaches a new normal, we take a more constructive stance on the laggards within European MedTech & Services where we see a higher degree of earnings visibility in a post COVID-19 world," the broker explains.
It says that this is "particularly the case at private hospital operators", for which Barclays particularly expects " structurally higher healthcare spend over the medium term and a likely more favorable regulatory backdrop going forward".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.